
Neurod1 and Ascl1 Convert Human Astrocytes into Neurons in Ex Vivo Culture of Human Brain Tissue
Brief intro:
- Author: Liang Xu, Qing-Song Wang, Jian-Cheng Liao, Jia-Jun Zheng, Bing Qin, Wen Li, Jia-Xuan Zhang, Wei Li, Xiang-Yu Wang, Mao-Ying Zhang, Gong Chen
- Journal: Neurology eJournal
- Doi: https://www.doi.org/10.2139/ssrn.4378268
- Publication Date: 2023 Mar 21
Products/Services used in the paper
Quotation shows PackGene:Adeno-associated virus (AAV): AAV9 GFAP::Cre, AAV9 CAG::Flex-GFP and AAV9 CAG::Flex-NeuroD1-GFP were produced by PackGene Biotech.
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:human brain slices
Abstract
Transcription factor-mediated cell conversion has been reported in the central nervous system (CNS) of both rodents and non-human primates (NHPs). In particular, astrocyte-to-neuron (AtN) conversion has been achieved in the brain and spinal cord of animal models of neurological disorders for neural regeneration and repair. However, whether AtN conversion can be ultimately used for human brain repair in patients is still unknown. To investigate the applicability of AtN conversion technology in human brain, we established a long-term ex vivo culture system using human brain tissue that is surgically removed from epileptic patients to directly test AtN conversion in human astrocytes. We demonstrate that both neural transcription factors NeuroD1 and Ascl1 can convert human astrocytes into neurons. Importantly, both immunostaining and electrophysiological recordings revealed that the astrocyte-converted neurons showed immature properties during initial 1-2 weeks of conversion, and then acquired more mature properties after 3-4 weeks of conversion. These studies in ex vivo human brain tissue pave a stepping stone toward future clinical trials using transcription factor-based AtN conversion approach to treat neurological disorders.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
